Evidence map›Paper›PMID 27028065›Full record

ArticleInvestigative ophthalmology & visual science2016

Digoxin Inhibits Induction of Experimental Autoimmune Uveitis in Mice, but Causes Severe Retinal Degeneration.

Samuel J H Hinshaw, Osato Ogbeifun, Wambui S Wandu, Cancan Lyu, Guangpu Shi, Yichao Li, Haohua Qian, Igal Gery

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Retinoschisin and Cardiac Glycoside Crosstalk at the Retinal Na/K-ATPase.Investigative ophthalmology & visual science · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Samuel J H HinshawLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Osato OgbeifunLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Wambui S WanduLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Cancan LyuLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Guangpu ShiLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Yichao LiVisual Function Core, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Haohua QianVisual Function Core, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
Igal GeryLaboratory of Immunology National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States.
National Institutes of Health · USNational Eye Institute · US

Funding

Visual Function CoreZICEY000503 · NEI · NATIONAL EYE INSTITUTE · PI QIAN, HAOHUA · 2011 to 2025
$12.3M
Immune Responses To Ocular AntigensZIAEY000069 · NEI · NATIONAL EYE INSTITUTE · PI GERY, IGAL · 2009 to 2017
$9.2M
Histopathology CoreZICEY000461 · NEI · NATIONAL EYE INSTITUTE · PI SCHNEEWEIS, DAVID · 2009 to 2022
$7.7M
Evaluation of Visual Function in Animal ModelsZIAEY000530 · NEI · NATIONAL EYE INSTITUTE · PI QIAN, HAOHUA · 2013 to 2025
$1.8M
Intramural NIH HHS
6 · The paper itself

Abstract

purposeDigoxin, a major medication for heart disease, was recently reported to have immunosuppressive capacity. Here, we determined the immunosuppressive capacity of digoxin on the development of experimental autoimmune uveitis (EAU) and on related immune responses.

methodsThe B10.A mice were immunized with interphotoreceptor retinoid-binding protein (IRBP) and were treated daily with digoxin or vehicle control. On postimmunization day 14, the mouse eyes were examined histologically, while spleen cells were tested for cytokine production in response to IRBP and purified protein derivative. The immunosuppressive activity of digoxin was also tested in vitro, by its capacity to inhibit development of Th1 or Th17 cells. To investigate the degenerative effect of digoxin on the retina, naïve (FVB/N × B10.BR)F1 mice were similarly treated with digoxin and tested histologically and by ERG.

resultsTreatment with digoxin inhibited the development of EAU, as well as the cellular response to IRBP. Unexpectedly, treatment with digoxin suppressed the production of interferon-γ to a larger extent than the production of interleukin 17. Importantly, digoxin treatment induced severe retinal degeneration, determined by histologic analysis with thinning across all layers of the retina. Digoxin treatment also induced dose-dependent vision loss monitored by ERG on naïve mice without induction of EAU.

conclusionsTreatment of mice with digoxin inhibited the development of EAU and cellular immune response to IRBP. However, the treatment induced severe damage to the retina. Thus, the use of digoxin in humans should be avoided due to its toxicity to the retina.

Indexed as

Diabetes Mellitus, Type 1AnimalsDigoxinDisease Models, AnimalEnzyme InhibitorsFemaleImmunity, CellularMiceRetinal DegenerationSeverity of Illness IndexUveitisDigoxinEnzyme Inhibitors

Identifiers

PMID27028065
PMCPMC4821074
OpenAlexW2323926031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.